Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.

Kilpatrick M, Gundersen P, O'Reilly K, Goyal S, Sun L, Kim P, Carlisle J

Open source

DOI
10.1016/j.cllc.2026.05.001
Published
2026 Jul
Container
Clinical lung cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2026.05.001,
  title = {Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.},
  author = {Kilpatrick M and Gundersen P and O'Reilly K and Goyal S and Sun L and Kim P and Carlisle J},
  year = {2026},
  journal = {Clinical lung cancer},
  doi = {10.1016/j.cllc.2026.05.001},
  url = {https://doi.org/10.1016/j.cllc.2026.05.001}
}

RIS

TY  - JOUR
TI  - Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.
AU  - Kilpatrick M
AU  - Gundersen P
AU  - O'Reilly K
AU  - Goyal S
AU  - Sun L
AU  - Kim P
AU  - Carlisle J
PY  - 2026
JO  - Clinical lung cancer
DO  - 10.1016/j.cllc.2026.05.001
UR  - https://doi.org/10.1016/j.cllc.2026.05.001
ER  - 

APA

M, K., P, G., K, O., S, G., L, S., P, K., & J, C. (2026). Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2026.05.001

Source records